Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + Chemotherapy in Metastatic Colorectal Cancer
NCT00111761Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2002
- Primary completion
- Feb 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of panitumumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Amgen. Primary endpoint: Number of Participants With Grade 3 or Grade 4 Diarrhea. Started Jul 2002; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00111761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111761.